Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - carcinom, pulmonar non-celulă mică - alte medicamente antineoplazice, inhibitori de proteinkinază - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

astrazeneca ab - osimertinibum - comprimate filmate - 80 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

astrazeneca ab - osimertinibum - comprimate filmate - 40 mg

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - osimertinib - compr. film. - 40mg - alte antineoplazice inhibitori de protein-kinaza

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - osimertinib - compr. film. - 80mg - alte antineoplazice inhibitori de protein-kinaza

Uniunea Europeană - română - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - agenți antineoplazici - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Uniunea Europeană - română - EMA (European Medicines Agency)

roche registration gmbh - cobimetinib hemifumarat - melanomul - agenți antineoplazici - cotellic este indicat pentru utilizarea în combinaţie cu vemurafenib pentru tratamentul pacienţilor adulţi cu melanom metastatic sau unresectable cu o mutatia braf v600.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

f.hoffmann-la roche, ltd. - cobimetinibum - comprimate filmate - 20 mg

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

roche pharma ag - germania - cobimetinibum - compr. film. - 20mg - inhibitori de protein-kinaza inhibitori ai proteinei kinazei activate de mitogen (mek)

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

zentiva s.a. - romania - voriconazolum - compr. film. - 200mg - antimicotice de uz sistemic derivati de triazol